High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: Technical issues and results of a phase I/II trial

International Journal of Radiation Oncology Biology Physics

Volumn 54, Issue 2, 2002, Pages 348-356

  Rosenman, Julian G ^a   Halle, Jan S ^a   Socinski, Mark A ^a   Deschesne, Katharin ^a   Moore, Dominic T ^a   Johnson, Harold ^a   Fraser, Robert ^b   Morris, David E ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b CAROLINAS MEDICAL CENTER   (United States)

Author keywords

Combined modality therapy; High dose radiation; Stage III NSCLC

Indexed keywords

CHEMOTHERAPY; PATIENT TREATMENT; PULMONARY DISEASES; RADIOTHERAPY; TUMORS;

LUNG CANCER;

ONCOLOGY;

ANTACID AGENT; ANTIFUNGAL AGENT; ANTIMIGRAINE AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CARBOPLATIN; LIDOCAINE; PACLITAXEL; PROTON PUMP INHIBITOR; SUCRALFATE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESOPHAGITIS; FATIGUE; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALAISE; MALE; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION PNEUMONIA; SAFETY; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; ESOPHAGITIS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT FAILURE;

EID: 0036803119     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)02958-9     Document Type: Article

References (34)

1. Greenlee R.T., Hill-Harmon M.B., Murray T., Thun M. Cancer Statistics, 2001. CA Cancer J Clin. 51:2001;15-36.
2. Detterbeck F.C. Diagnosis and treatment of lung cancer an evidence-based guide for the practicing physician . 2000;WB Saunders, Philadelphia.
3. Bülzebruk H., Bopp R., Drings P., et al. New aspects in the staging of lung cancer Prospective validation of the International Union Against Cancer TNM classification . Cancer. 70:1992;1101-1110.
4. Dillman R.O., Herndon J., Seagren S.L., et al. Improved survival in stage III non small cell lung cancer Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial . J Natl Cancer Inst. 88:1996;1210-1215.
5. Sause W.T., Scott C., Taylor S., et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588 Preliminary results of a phase III trial in regionally advanced unresectable non-small cell lung cancer . J Natl Cancer Inst. 87:1995;198-205.
6. Cullen M.H., Billingham L.J., Woodroffe C.M., et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer Effects on survival and quality of life . J Clin Oncol. 17:1999;3188-3194.
7. LeChevalier T., Arriagada R., Quiox E., et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung cancer An analysis of a randomized trial in 353 patients . J Natl Cancer Inst. 83:1991;417-423.
8. Schaake-Konig C., van den Bogaert W., Dalesio O., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med. 326:1992;524-530.
9. Arriagada R., LeChevalier T., Quoix E., et al. ASTRO Plenary . Effects of chemotherapy on locally advanced non-small cell lung cancer A randomized study of 353 patients . Int J Radiat Oncol Biol Phys. 20:1991;1183-1190.
10. Perez C.A., Stanley K., Grundy G., et al. Impact of radiation technique and tumor extent on tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung Report by the RTOG . Cancer. 50:1982;1091-1099.
11. Socinski M.A., Rosenman J.G., Halle J., et al. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B non-small cell lung cancer A modified phase I/II trial . Cancer. 92:2001;1213-1223.
12. Beahrs O.H., Henson D.E., Hutter R.V.P., et al. Manual for staging of cancer. 1988;155 JB Lippincott, Philadelphia.
13. Calvert A.H., Newell D.R., Gumbrell L.A., et al. Carboplatin dosage Prospective evaluation of a single formula based on renal function . J Clin Oncol. 7:1989;1748-1756.
14. Sailer S.L., Chaney E.L., Rosenman J.G., et al. Treatment planning at the University of North Carolina at Chapel Hill. Semin Radiat Oncol. 2:1992;267-273.
15. Rosenman J., Miller E., Cullip T., Tracton G. Image registration An essential part of radiation therapy treatment planning . Int J Radiat Oncol Biol Phys. 40:1998;197-205.
16. Graham M.V., Purdy J.A., Emami B., et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 45:1999;323-329.
17. Miller E.P., Chang S.X., Rosenman J., et al. Dose gradient optimization via compensator Construction and clinical assurance . Med Phys. 23:1996;1170.
18. Antonadou D., Coliarakis N., Synodinou M., et al. Randomized phase III trial of radiation treatment ± amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys. 51:2001;915-922.
19. Schell M.J., Singh B. The reduced monotonic regression method. J Am Stat Assoc. 92:1997;128-135.
20. Furuse K., Fukuoka K.M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol. 17:1999;2692-2699.
21. Curran W.J. Jr, Scott C., Langer C., et al. Phase III comparison of sequential versus concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer (NSCLC) Initial report of RTOG 9410 . [Abstract] Proc ASCO. 19:2000;484a.
22. Zelefsky M.J., Fuks Z., Hunt M., et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 166:2001;876-881.
23. White J.E., Chen T., McCracken J., et al. The influence of radiation therapy quality control on survival, response and sites of relapse in oat cell carcinoma of the lung. Cancer. 50:1982;1084-1090.
24. Byhardt R.W., Martin K., Pajak T.F., et al. The influence of field size and other treatment factors on pulmonary toxicity following hyperfractionated irradiation for inoperable non-small cell lung cancer (NSCLC) - Analysis of a Radiation Therapy Oncology Group (RTOG) protocol. Int J Radiat Oncol Biol Phys. 27:1993;537-544.
25. Dillman R.O., Seagren S.L., Propert K.J., et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 323:1990;940-945.
26. Schaake-Konig C., Kirkpatrick A., Kroger R., et al. The need for immediate monitoring of treatment parameters and uniform study of the EORTC Radiotherapy and Lung Cancer Cooperative Groups. Eur J Cancer. 27:1991;616-619.
27. Vanuytsel L.J., Vansteenkiste J.F., Stroobants S.G., et al. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol. 55:2000;317-324.
28. Senan S., Burgers J.A., Samson M.J., et al. Can elective nodal irradiation be omitted in Stage III non-small-cell lung cancer? An analysis of recurrences after sequential chemotherapy and "involved-field" radiotherapy. [Abstract] Int J Radiat Oncol Biol Phys. 51:(Suppl. 1):2001;21-22.
29. Hayman J.A., Martel M.K., Ten Haken R.K., et al. Dose escalation in non-small cell lung cancer using three-dimensional conformal radiation therapy Update of a phase I trial . J Clin Oncol. 19:2001;127-136.
30. Daly B.D.T., Mueller J.D., Failing L.J., et al. N2 lung cancer Outcome in patients with false-negative computed tomographic scans of the chest . J Thorac Cardiovasc Surg. 105:1993;904-911.
31. Cox J.D., Azarnia N., Byhardt R.W., et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy Possible survival benefit with ≥69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: Report of Radiation Therapy Oncology Group 83-11 . J Clin Oncol. 8:1990;1543-1555.
32. Maguire P.D., Marks L.B., Sibley G.S., et al. 73.6 Gy and beyond Hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer . J Clin Oncol. 19:2001;705-711.
33. Sim S., Rosenzweig K.E., Schindelheim R., et al. Induction chemotherapy plus three-dimensional conformal radiation therapy in the definitive treatment of locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 51:2001;660-665.
34. Graham M.V., Winter K., Purdy J.A., et al. Preliminary results of a Radiation Therapy Oncology Group trial (RTOG 9311) A dose escalation study using 3D conformal radiation therapy in patients with inoperable nonsmall cell lung cancer . [Abstract] Int J Radiat Oncol Biol Phys. 51:(Suppl. 1):2001;19-20.